Document Type : Original Article
Author
Abstract
Background: Bladder cancer is one of the most common tumors of the urinary tract and one of the main causes of cancer-related death in males. It is the ninth most prevalent cancer globally. The microenvironment of a bladder tumour is rich in growth factors/inflammatory cytokines that can induce tumour growth/progression and suppress the immune system. Methods: This is a case-control study in which patients with Bladder Cancer were enrolled. Blood and urine samples were obtained from 50 diagnosed patients and 96 healthy people as a control group. Interleukins levels were evaluated. In this study quantitative levels of serum and urine interleukin2 and interleukin 10 in bladder cancer patients were evaluated by using ELISA test. Results: It has been found that the level of these cytokines was higher in all patients as compared with their level at the control group. There were high significant differences in the levels of interleukin-2 between patients and controls (P=0.0001), which is higher in the patient group. Additionally, the serum IL-2, (133.5 > 0.48) found to be significantly higher than urine IL-2, (113.5 > 0.44), (P= 0.021). While there was no significant difference in the levels between serum and urine IL -10 (P= 0.825) in patients and control. These results indicated that interleukin 2 is an indicator that predicts the progression or recurrence of the disease. Conclusion: In Conclusion, Interleukins probably may play a role in predicting the progression of bladder cancer or the development of advanced disease. Serum and urine levels of cytokine increased in the patient’s comparison with the control. Also, the levels were higher in serum than the urine in patients
Keywords
)